Noteworthy Home-grown change at Regeneron

The broadening of Regeneron Pharmaceuticals Inc.'s strategic focus beyond neurological diseases eventually could change the character of the company, but the process will be a gradual one.

The Tarrytown, N.Y., company last week announced a series of preclinical discoveries representing new areas of focus, with potential in cancer, inflammation and muscle disorders. The discoveries include a novel class of cytokine antagonists, a family of ligands important for angiogenesis and a ligand for a muscle-specific growth factor receptor.